Euroopan unioni - suomi - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multiple myeloma - antineoplastiset aineet - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatidi - osteoporosis; osteoporosis, postmenopausal - kalsiumin homeostaasi - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatidi - osteoporosis; osteoporosis, postmenopausal - kalsiumin homeostaasi - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ekulitsumabi - hemoglobinuria, paroxysmal - immunosuppressantit - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

Euroopan unioni - suomi - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastiset aineet - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - deferiproni - beta-thalassemia; iron overload - kaikki muut terapeuttiset tuotteet - ferriproxin yksinään on tarkoitettu raudan ylikuormitus potilailla thalassaemia suuria, kun nykyinen kelaatiohoidon hoito on kontraindisoitu tai puutteellista hoitoa. ferriproxia yhdessä toisen kelatoi tehokkaasti on tarkoitettu potilaille, joilla on talassemia major, kun yksinään mitään rautaa kelatoi tehokkaasti on tehoton, tai kun ehkäisyyn tai hoitoon hengenvaarallisia seurauksia raudan ylikuormitus (lähinnä sydämen ylikuormitus) oikeuttaa nopea tai intensiivinen korjaus.

Euroopan unioni - suomi - EMA (European Medicines Agency)

theravia - hydroksikarbamidi - anemia, sickle cell - antineoplastiset aineet - siklos on tarkoitettu toistuvien kivuliaita verisuonten tukkeutumisen aiheuttamia kriisitilanteita mukaan lukien akuutti rinnassa oireyhtymä lapsilla ja aikuisilla potilailla, jotka kärsivät oireista sirppi-solun oireyhtymä.

Suomi - suomi - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - linezolid - infuusioneste, liuos - 2 mg/ml - linetsolidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

noridem enterprises limited - sugammadex sodium - injektioneste, liuos - 100 mg/ml - sugammadeksi